
IPCA Q2 FY27: Consolidated PAT +33% YoY to ₹375 Cr (~17% adjusted), revenue +14%
Ipca Laboratories' consolidated PAT (owners) came in at ₹375.13 Cr for Q2 FY27, up 32.8% YoY from ₹282.57 Cr, on consolidated revenue of ₹2,909.94 Cr, up 13.8% YoY (+4.4% QoQ). Standalone revenue grew faster YoY (16.9%) than consolidated, while standalone PAT grew slower (27.1% vs 32.8%) — a >3-point divergence in both directions that reflects the subsidiary mix (Unichem/exports) rather than any inconsistency in the underlying print; both bases point the same direction. This is the primary, consolidated-basis read. The reported 32.8% YoY PAT jump is flattered by one-off items on both sides of the comparison: this quarter carries a ₹24.26 Cr exceptional 'Provision for Claims' (Perindopril UK litigation at Niche Generics, a Unichem step-down subsidiary), while the year-ago quarter absorbed a larger ₹58.26 Cr European Commission interest-settlement charge on the same Unichem/Niche litigation. Stripping both out (pre-tax, since the filing doesn't separately disclose tax effects on exceptional items) gives adjusted PAT growth of roughly 17% YoY — still healthy but well below the headline. Margins expanded YoY on both measures: NPM (PAT/total income) rose to 12.8% from 10.9%, and EBITDA margin (PBT excl. exceptional + finance cost + D&A, over revenue) rose to ~24.0% from ~22.4%. Sequentially, PAT fell 6.7% from ₹401.89 Cr in Q1 FY27 and OPM eased from ~24.9%, with the Q2 claims provision the main driver of that dip rather than any operating deterioration — revenue still rose 4.4% QoQ. No reliable Street consensus for this specific quarter's PAT/EBITDA could be sourced via web search, so vsStreet is marked unknown rather than guessed. Against the company's own guidance from the Q1 FY27 call — FY27 revenue growth raised to 14-16% and EBITDA margin raised to ~23% — the half-year run-rate is tracking ahead: H1 FY27 consolidated revenue is up 17.1% YoY and H1 OPM works out to ~24.5%, both above the raised bars, so the quarter reads as a guidance beat rather than merely on-track. This is consistent with the bullish, confident tone management struck on the August 2026 call. The quarter's other disclosed developments — board approval on November 5, the pending Krebs Biochemicals amalgamation (no P&L effect yet, pending approvals), and the routine insider-trading window closure ahead of results — are procedural and don't move the numbers. No management press release text was available in this filing bundle to cross-check against management's own framing of the quarter. Going into Q3, the two swing factors are whether the Niche/Unichem claims provision proves final or needs topping up, and whether H2 margins hold near the 23%+ guided level after this quarter's sequential easing.
Key Highlights
- Consolidated revenue ₹2,909.94 Cr, +13.8% YoY / +4.4% QoQ; H1 FY27 revenue ₹5,698.04 Cr, +17.1% YoY — running above the raised 14-16% FY27 guidance
- Consolidated PAT (owners) ₹375.13 Cr, +32.8% YoY reported; adjusted for one-offs on both sides, YoY growth is ~17%
- One-off: ₹24.26 Cr exceptional 'Provision for Claims' this quarter (Perindopril UK litigation, Niche Generics/Unichem) vs ₹58.26 Cr European Commission interest-settlement charge in the year-ago quarter
- Margins expanded YoY — NPM to 12.8% from 10.9%, EBITDA margin to ~24.0% from ~22.4%; H1 OPM ~24.5% is already above the raised ~23% guidance
- QoQ PAT down 6.7% from ₹401.89 Cr in Q1 FY27, driven by this quarter's claims provision rather than operating weakness (revenue still +4.4% QoQ)
- Standalone: revenue ₹2,255.61 Cr (+16.9% YoY), PAT ₹387.29 Cr (+27.1% YoY), EPS ₹15.27, no exceptional items this quarter
- Non-controlling interest (largely Unichem minority) absorbed ₹14.19 Cr of the ₹389.32 Cr pre-NCI consolidated profit
Price Impact
More from IPCALAB